IN8BIO INC
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
INAB$0.94+1.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(In thousands)
| Year EndedDecember 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating activities | ||
| Net loss | $(30,007) | $(28,521) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 962 | 147 |
| Non-cash stock-based compensation | 4,370 | 3,467 |
| Amortization of finance lease right-of-use assets | 871 | 461 |
| Amortization of operating lease right-of-use assets | 668 | 495 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 689 | (2,093) |
| Other non-current assets | — | (97) |
| Accounts payable | (981) | 1,510 |
| Accrued expenses and other current liabilities | 796 | 924 |
| Short-term operating lease liabilities | 112 | 112 |
| Long-term operating lease liabilities | (820) | (526) |
| Net cash used in operating activities | (23,340) | (24,121) |
| Investing activities | ||
| Purchases of property and equipment | (405) | (3,689) |
| Construction in progress | (195) | (16) |
| Net cash used in investing activities | (600) | (3,705) |
| Financing activities | ||
| Proceeds from private placement common stock, net of issuance costs | 10,184 | — |
| Proceeds from private placement warrants, net of issuance costs | 3,278 | — |
| Proceeds from the issuance of common stock, net of issuance costs | 14,380 | 9,542 |
| Principal payments on finance leases | (798) | (615) |
| Proceeds from exercise of common stock options | — | 61 |
| Net cash provided by financing activities | 27,044 | 8,988 |
| Net increase (decrease) in cash and restricted cash | 3,104 | (18,838) |
| Cash and restricted cash at beginning of year | 18,434 | 37,272 |
| Cash and restricted cash at end of year | $21,538 | $18,434 |
| Supplemental disclosure of non-cash operating, financing and investing information: | ||
| Construction in progress included in accounts payable | $— | $13 |
| Property and equipment in accounts payable | $— | $356 |
| Transfer of construction in progress to property and equipment | $29 | $403 |
| Initial measurement of finance lease right-of-use assets | $536 | $1,448 |
| Initial measurement of operating lease right-of-use assets | $— | $3,046 |
| Lease modification of finance lease right-of-use assets and liabilities | $7 | $— |
| Initial measurement of lease liabilities | $— | $4,286 |
Statements of Cash Flows Continued
(In thousands)
The following table provides a reconciliation of cash and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows:
| December 31,2023 | December 31,2022 | |
|---|---|---|
| Cash, end of year | $21,282 | $18,182 |
| Restricted cash, end of year | 256 | 252 |
| Cash and restricted cash, end of year | $21,538 | $18,434 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.